Get started
Novavax, Inc.Novavax, Inc.Novavax, Inc.

Novavax, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsBondsETFs

NVAX trade ideas

NVAX -- Crazy climb!! In try to finding vaccine....NVAX -- Crazy climb!! In a try to reach a vaccine.... ZACKS pick The company’s expected earnings growth rate for the current year is 46% compared with the Zacks Medical - Biomedical and Genetics industry’s projected earnings growth of 8.1%. Novavax, Inc. NVAX is a late-stage biotechnology company that focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Post the virus outbreak, the company has launched a program for the coronavirus vaccine. Novavax already boasts success in vaccine development for the MERS and SARS strains. Be careful with Pharmicuticals... can be great BUT can reverse VERY VERY quickly. Buy moderate lows. Can be shorted because of this. SPIKING ON NEWS!! TODAY. ___________________________________ Disclaimer: Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any comments and analysis seen here are personal opinions, and we are not registered or licensed in any jurisdiction whatsoever to provide any investing advice. Any analysis, charting and comments should never be used for the purposes of assisting in any advisory decisions with any stock purchase or sale, and never to be used on the basis of making any kind of investment decisions. It is for the sole purposes of opinions and thoughts only of the markets. Thank you.
NASDAQ:NVAX
by eziolisi_Investments
2
Novavax Coronavirus StockNovavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
NASDAQ:NVAXLong
by DEXWireNews
NVAX coronavirus panic.NVAX coronavirus panic. Currently, several biotech shares rose significantly yesterday. The driving force is a fundamental fear of the coronavirus. NVAX is one of the potential candidates who can isolate and solve the problem. The fair value of NVAX stock is currently around USD 11.5. Technically, the stock price is in the right place. But what about panic? Is technology down there? ... Not sure. With braver target prices, the next upswing can be exploited. Let's start with the most basic target price rule. The target price is the sum of the closing value of the given trading time frame and the ATR of the two farthest moving averages measured at the closing values. Where can we be brave here? There to raise the timeframe to W1. In this timeframe, we generate a closing value ATR and this can give you a target price level. So if we calculate a target price using W1 ATR calculation, then the target price can be 33.6usd. A 231% increase from the current level. This analysis is highly speculative. But in panic it can easily work.
NASDAQ:NVAX
by meszaros
24
NVAX Bullish PennantThese are my thoughts and positions, 1. Appears that NVAX has opportunity for breakout as pennant matures 2. Price is trending healthily above 200 EMA.Price is also above and respecting the 50 EMA like they're in a long term committed relationship celebrating Valentine's day. 3. Notice the mid term higher lows signifying bullish strength 4.Support market structure at $2.10 -2.20 is displaying strength. 5. Profit Target One $4.2, Stop-Loss $1.47 6. Bullish on NVAX and mid to long term trend continuation.
NASDAQ:NVAX
by Michael-David